Search Results 331-340 of 18618 for Appendix

  1. Breast cancer - Doctors and departments - Mayo Clinic

    ... Appendix cancer. Show more areas of focus for Sanjay P. Bagaria, M.D.. Saranya Chumsri, M.D.. Oncologist. Jacksonville, FL. Areas of focus ...

  2. Breast cancer - Doctors and departments - Mayo Clinic

    ... Appendix cancer. Show more areas of focus for Sanjay P. Bagaria, M.D.. Saranya Chumsri, M.D.. Oncologist. Jacksonville, FL. Areas of focus ...

  3. Pancreatitis - Doctors and departments - Mayo Clinic

    ... Appendix cancer, Gastrointestinal stromal tumor, Enlarged spleen, Stage 4 colorectal cancer, Recurrent cancer, Duodenal cancer, Bile duct injury, Bile duct ...

  4. Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients - Mayo Clinic

    No treatment with high dose steroids for GVHD (up to 20 mg Prednisolone or equivalent, Appendix G). No treatment with immunosuppressive drugs with the ...

  5. Rapid-Plan Knowledge-Based Planning vs. Human-Driven Planning for Prostate Cancer Radiotherapy - Mayo Clinic

    - appendix II). 4. Planned definitive dose radiotherapy to the prostate or prostate bed. 5. ECOG performance status 0-2 (appendix II) assessed within 90 ...

  6. MAYO STANDARDS AND CODE OF CONDUCT

    Appendix I. MAYO STANDARDS AND CODE OF CONDUCT. FOR HEALTHCARE INDUSTRY AND SUPPLIER/SALES REPRESENTATIVES. Mayo Clinic's code of conduct, integrity and ...

  7. Pancreatic neuroendocrine tumors - Doctors and departments - Mayo Clinic

    ... Appendix cancer, Gastrointestinal stromal tumor, Enlarged spleen, Stage 4 colorectal cancer, Recurrent cancer, Duodenal cancer, Bile duct injury, Bile duct ...

  8. Enlarged spleen (splenomegaly) - Doctors and departments - Mayo Clinic

    ... Appendix cancer, Gastrointestinal stromal tumor, Enlarged spleen, Stage 4 colorectal cancer, Recurrent cancer, Duodenal cancer, Bile duct injury, Bile duct ...

  9. Safusidenib Phase 2 Study In IDH1 Mutant Glioma - Mayo Clinic

    Patient did receive the prior therapy targeted to IDH1 mutation. 8. Patients taking substrates of cytochrome CYP2C8, CYP2C9, and CYP3A4 (See Appendix 7)

  10. A Study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diabetes - Mayo Clinic

    Is a woman of nonchildbearing potential (WONCBP) as defined in Appendix 4: Contraceptive and barrier guidance (Section 10.4). OR; Is a WOCBP and agrees to ...